IntroductIon Tobacco smoking is a major risk factor for cardiovascular diseases.
were mixed with 3.2% sodium citrate (9:1), centrifuged for 60 minutes, and stored at -80ºC. Plasma PAI-1 antigen and soluble TM levels were measured by immunoenzymatic assays (American Diagnostica, United States, and Diagnostica Stago, Asniéres, France, respectively). All measurements were performed by technicians blinded to the sample status. The coefficients of intra-and interassay variations were less than 7%.
Plasma ADMA concentrations were measured in EDTA plasma using high-performance liquid chromatography (HPLC) with precolumn derivatization as previously described. 20 In brief, equilibrated CBA columns (BountElut, Varian Inc., California, United States) were used for 3-fold flushing with 1 ml of plasma samples and then washed with methanol and distilled water. Then, the samples were eluted with 10% ammonia and dried. The sediment obtained was dissolved in 1 ml of water, the solution centrifuged, and the supernatant was subjected to HPLC using the ODS column (Fisher Scientific, St. Louis, Missouri, United States). The inter-and intraassay coefficients of variation for ADMA were below 7%.
Serum cotinine was extracted by the liquid--liquid extraction method as an internal standard and a deuterated cotinine was used. Cotinine levels were determined using gas chromatography tandem mass spectrometry. Chromatographic separation was performed with Thermo Scientific ITQ 1100 (Thermo Scientific, Woltham, Massachusetts United States) on a DB5MS column (30×0.25×0.25; Agilent Technology, United States). The temperature program of the column was applied as follows: 70ºC at baseline, then increased to 290ºC over the next 20 minutes, and maintained at 290ºC for 20 minutes. The calibration curve was linear between 2 and 500 ng/ml. The limit of the quantification of cotinine was 2 ng/ml. The inter-and intraassay coefficients of variation for low-and high-concentration of cotinine were below 10%.
Patients that declared to be nonsmokers and had cotinine levels exceeded 2 ng/ml were considered to be passive smokers and were included into the group with cotinine concentrations of <12 ng/ml. Patients with cotinine concentrations exceeding 12 ng/ml were considered to be smokers and were classified accordingly despite self-declared nonsmoking.
statistical analysis Statistical analysis was performed with the SAS® 9.3 software (SAS Institute, Cary, North Carolina, United States).
Most of the variables in the study interval were not normally distributed, as indicated by the Shapiro-Wilk test. The statistical distributions of biochemical parameters between patient groups were compared using the Wilcoxon rank-sum test or Kruskal-Wallis test. Categorical variables were compared by the χ 2 exact test. The SAS MULTTEST procedure was used to control significance level for multiple comparisons. Spearman rank correlation coefficients between of nicotine, is a specific biomarker of smoking and allows to distinguish active smokers from nonsmokers or second-hand smokers. [10] [11] [12] Endothelial dysfunction is typical of atherosclerotic vascular disease in its early stage. 13, 14 Reduced bioavailability of nitric oxide (NO) produced by endothelial synthase (eNOS) from L-arginine is partially associated with an increased formation of asymmetric dimethylarginine (ADMA), an eNOS inhibitor involved in endothelial damage and atherosclerosis. 15, 16 Thrombomodulin (TM), an integral transmembrane glycoprotein, is a sensitive marker of endothelial damage. TM exhibits prothrombotic effects including activation of protein C and inactivation of plasminogen activator inhibitor type-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor. TM deficiency may lead to increased activation of endothelial cells and progression of atherosclerosis. 17 Owing to its anticoagulant properties, TM plays an important role in the regulation of intravascular coagulation. It is also recognized as an early marker of atherosclerotic vascular disease. 18 Elevated plasma PAI-1 levels are a marker of endothelial damage associated with higher cardiovascular risk. 19 The aim of this study was to evaluate whether active and passive smoking may affect the markers of endothelial dysfunction in advanced atherosclerosis.
PAtIEnts And mEthods Patients
The study included 181 consecutive patients with stable coronary artery disease (CAD). In all patients, stenosis of more than 50% in at least 1 epicardial coronary artery was documented within the previous year. The exclusion criteria were as follows: acute infections, acute cardiovascular events within the preceding 6 months, end-stage kidney disease, cancer, severe chronic obstructive pulmonary disease, and anticoagulant therapy. All subjects either declared cessation of cigarette smoking within at least 3 months prior to examination or were current smokers who had smoked for at least 10 years. Diabetes mellitus was defined as the use of insulin or oral hypoglycemic agents. Renal failure was defined as serum creatinine exceeding 120 µmol/l. Family history of CAD was defined as having a parent or sibling with MI or coronary revascularization at the age of 50 years or younger.
The Bioethics Committee of the Jagiellonian University approved the study and all participants provided their written informed consent.
Laboratory tests Blood samples were obtained by venipuncture from the antecubital vein using minimal stasis after 12 hours of fasting. Lipid profiles, glucose, creatinine, blood cell and platelet counts were assayed by routine laboratory techniques. Plasma fibrinogen was determined using the von Clauss method. High-sensitivity C-reactive protein was measured by latex nephelometry (Siemens, Marburg, Germany). Plasma samples As shown in tAbLE 1, current smokers and nonsmokers did not differ with regard to the majority of the variables. Only creatinine levels were slightly higher in smokers.
Cotinine levels were higher in the group of current smokers. Eight patients (7.8%) in the group of self-declared nonsmokers had cotinine levels above 12 ng/ml, suggesting active smoking. These patients were regarded as smokers and included in the smoking group.
Plasma ADMA levels were 18% lower in nonsmokers compared with current smokers (P <0.0001). Similarly, plasma PAI-1 and TM levels were lower in nonsmokers (P <0.0001). Patients, without measurable serum cotinine had lower concentrations of ADMA, TM, and PAI-1 (P <0.0001) than the remaining patients. The highest levels of these parameters were observed in individual parameters were also computed along with their significance tests.
A linear multiple regression analysis was performed for both groups in addition to the combined data to identify factors that affect ADMA, TM, and PAI-1. To that end, a forward selection method was applied using a P value of less than 0.5 as the inclusion criterion. For the full model, the square of the multiple correlation coefficients was calculated, while for the model covariates the regression coefficients and squared partial correlation coefficients (using type II sum of squares) were computed. A P value of less than 0.05 was considered significant.
rEsuLts The study population comprised 181 patients with CAD, including 53 women and 128 men. There were 102 current smokers (56.4%). Abbreviations: ADMA -asymmetric dimethylarginine, BMI -body mass index, HDL-C -high-density lipoprotein cholesterol, hsCRP -high-sensitivity C-reactive protein, LDL-C -low-density lipoprotein cholesterol, NSTEMInon-ST-segment elevation myocardial infarction, STEMI -PAI-1 -plasminogen activator inhibitor-1, ST-elevation myocardial infarction, TC -total cholesterol, TM -thrombomodulin 0.53, P <0.0001), and PAI (r = 0.58, P <0.0001).
The positive correlations between ADMA and TM (r = 0.33, P <0.0001) and ADMA and PAI-1 (r = 0.40, P <0.0001) were also observed.
In the group of current smokers (n = 72), similar positive correlations between cotinine and ADMA (r = 0.72, P <0.0001), TM (r = 0.43, P = 0.0002), and PAI-1 (r = 0.37, P = 0.0003) were noted. Apart from the markers of endothelial dysfunction, cotinine concentratiosn correlated with blood platelet count (P = 0.031). PAI-1 was also found to correlate with ADMA (r = 0.35, P = 0.003), TM (r = 0.27, P = 0.023), and low-density lipoprotein cholesterol (r = 0.27, P = 0.022). Of all the variables studied in the regression analysis, correlations were observed between ADMA and cotinine (r = 0.64, P <0.001) and ADMA and creatinine (r = the group with cotinine levels exceeding 12 ng/ml (P <0.05). The highest ADMA levels were observed in patients with cotinine levels exceeding 12 ng/ml (P <0.0001), while there were no differences between patients with undetectable cotinine and those with its levels of less than 12 ng/ml. The lowest TM and PAI-1 levels were observed in the group with undetectable cotinine levels, higher in the group with cotinine levels of less than 12 ng/ml, and the highest in the group with cotinine levels exceeding 12 ng/ml (tAbLE 2). There was no association between endothelial dysfunction, clinical parameters, and treatment of CAD. In the whole patient group, there were significant correlations (as indicated by Spearman correlation coefficient) between cotinine and ADMA (r = 0.71, P <0.0001), TM (r = A number of studies have shown that components of tobacco smoke exert adverse effects on the cardiovascular system. 1,3,11 Our study conducted in older patients with severe CAD demonstrates that exposure to tobacco smoke is potent enough to enhance endothelial cell damage despite the presence of several strong cardiovascular risk factors. Furthermore, cotinine has been identified as an independent predictor of ADMA, TM, and PAI-1 levels in advanced CAD. Our findings provide additional evidence for the harmful effects of passive and active smoking in individuals with atherosclerotic vascular disease.
Based on the available data, we used serum cotinine levels to distinguish active and passive smokers from nonsmokers not exposed to tobacco smoke. 6, 12 In our study, we used a cut-off value of 12 ng/ml to distinguish between smokers and exposed individuals, and those with no cotinine in serum (levels below 2 ng/ml) were classified as nonsmokers. The presence of cotinine in the group of nonsmokers indicates that the measurement of serum cotinine levels is more reliable than self-reported nonsmoking.
Significant associations between ADMA, TM, and PAI-1 were shown in patients with detectable serum cotinine levels. Of note, regression analysis showed significant correlations between 0.32, P <0.001). A correlation between cotinine and ADMA was also present in the group with cotinine levels exceeding 2 ng/ml (r = 0.45, P <0.05) as well as in the group with cotinine exceeding 12 ng/ml (r = 0.54, P <0.0001). TM was found to correlate with cotinine in the whole study group (r = 0.34, P <0.001) and, separately, in smokers (r = 0.38, P <0.01). In the group with cotinine levels of less than 2 ng/ml, TM also correlated with the body mass index (r = 0.27, P <0.01). PAI-1 correlated with cotinine levels in all study subjects (r = 0.34, P <0.001; tAbLE 3).
In the group with cotinine exceeding 12 ng/ml, the incidence of MI was higher than in the other groups (46.91% vs. 56.06%, P = 0.002; tAbLE 4).
For the whole study group, a multivariate analysis showed that cotinine was an independent predictor of ADMA, TM, and PAI-1 levels.
dIscussIon Our study demonstrated that current smoking in patients with advanced atherosclerosis is associated with worsening of endothelial damage, which is reflected by elevated ADMA, TM, and PAI-1 concentrations in plasma. To our knowledge, this study is the first to show that despite long-lasting endothelial injury in advanced CAD, continued cigarette smoking is still able to enhance endothelial damage via elevated ADMA associated with increased inhibition of fibrinolysis. on fibrin clot properties. 21, 26, 27 The present study supports the concept that despite the presence of several cardiovascular risk factors known to impair fibrinolysis, including hypertension, diabetes, and previous cardiovascular events, 26, 27 current smoking, reflected by elevated cotinine levels, can still increase the release of PAI-1 and, consequently, further attenuate plasmin generation in patients with CAD.
Another interesting finding is the positive association between cotinine and soluble TM in advanced CAD. In the general population, soluble TM largely synthesized by vascular endothelial cells is weakly associated with cardiovascular risk factors including smoking. 28 To our knowledge, this report is the first to have shown this association in advanced CAD, in which endothelial injury is a typical feature. 29 Plasma TM levels are increased in smokers. Given the robust data on the effects of TM on cellular proliferation, adhesion, and inflammation, all of which ADMA, TM, and PAI-1 and cotinine in all analyzed subgroups.
Elevated levels of endothelial dysfunction markers in patients with advanced atherosclerosis exposed to tobacco smoke indicate progressive endothelial damage associated with smoking. Sustained activation of the endothelium leads to decreased bioavailability of NO by increasing the production of ADMA and the activity of free radicals. Endothelial dysfunction that accompanies atherosclerosis, in addition to the reduced NO availability, is also characterized by an increased synthesis of prothrombotic factors and the impairment of fibrinolytic activity. 15, [21] [22] [23] The latter observation based on increased circulating PAI-1 levels is particularly important given evidence for the links between impaired fibrinolysis, largely determined by PAI-1 levels, and the risk of MI. 17, 19, 24, 25 Several studies have demonstrated poor fibrinolytic capacity in smokers and significant negative effect of active smoking tAbLE 4 Comparison of clinical and biochemical parameters based on serum cotinine levels
Parameter
Cotinine levels P value <LOD (n = 81) ≤12 ng/ml (n = 34) >12 ng/ml (n = 52) <LOD ->12 
